Gilead Sciences, China's Qinhao Pharmaceutical Sign Global Deal for Tumor Therapy Candidate

robot
Abstract generation in progress

Gilead Sciences has signed a global agreement with China’s Qinhao Pharmaceutical for a tumor therapy candidate. This deal was announced on February 17, 2026, and is reported by MT Newswires. Further details about the specific therapy candidate were not immediately available in the provided text.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)